Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1

19 Feb 2018

Abstract excerpt

HIV-1 latent reservoirs harbouring silenced but replication-competent proviruses are a major obstacle against viral eradication in infected patients. The "shock and kill" strategy aims to reactivate latent provirus with latency reversing agents (LRAs) in the presence of antiretroviral drugs, necessitating the development of effective and efficient LRAs. We screened a chemical library for potential LRAs and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to HIV Research and Treatment
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29476067
DOI: 10.1038/s41598-018-21942-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1PMID 29476067Read ↗

Are BET Inhibitors yet Promising Latency-Reversing Agents for HIV-1 Reactivation in AIDS Therapy?Semantic proximity Read ↗

An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene ExpressionSemantic proximity Read ↗

A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other “Shock” DrugsSemantic proximity Read ↗

BET bromodomain inhibition as a novel strategy for reactivation of HIV-1Semantic proximity Read ↗

Inhibition of the TRIM24 bromodomain reactivates latent HIV-1Semantic proximity Read ↗

Inhibition of the TRIM24 bromodomain reactivates latent HIV-1Semantic proximity Read ↗

Inhibition of the TRIM24 bromodomain reactivates latent HIV-1Semantic proximity Read ↗

Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agentsSemantic proximity Read ↗

Reactivation of Latent HIV-1 by Inhibition of BRD4Semantic proximity Read ↗

A New Small-Molecule Compound, Q308, Silences Latent HIV-1 Provirus by Suppressing Tat- and FACT-Mediated TranscriptionSemantic proximity Read ↗

KDM5A/B contribute to HIV-1 latent infection and survival of HIV-1 infected cellsSemantic proximity Read ↗

Mechanistic insights and <i>in vivo</i> HIV suppression by the BRD4-targeting small molecule ZL0580Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.